BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34269308)

  • 21. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Azemoto R; Shinozaki M; Yoshikawa M; Yokosuka O
    PLoS One; 2015; 10(4):e0125244. PubMed ID: 25919025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.
    Op den Winkel M; Nagel D; Op den Winkel P; Paprottka PM; Schmidt L; Bourhis H; Trojan J; Goeller M; Reiter FP; Stecher SS; De Toni EN; Gerbes AL; Kolligs FT
    Digestion; 2019; 100(1):15-26. PubMed ID: 30282074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.
    Kim BK; Shim JH; Kim SU; Park JY; Kim DY; Ahn SH; Kim KM; Lim YS; Han KH; Lee HC
    Liver Int; 2016 Jan; 36(1):92-9. PubMed ID: 25950442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
    Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
    PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
    Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
    Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma.
    Vogeler M; Mohr I; Pfeiffenberger J; Sprengel SD; Klauss M; Teufel A; Chang DH; Springfeld C; Longerich T; Merle U; Mehrabi A; Weiss KH; Mieth M
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):1033-1050. PubMed ID: 32107625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Prajapati HJ; Kim HS
    PLoS One; 2017; 12(2):e0170750. PubMed ID: 28170405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria.
    Fu H; Zheng J; Cai J; Zeng K; Yao J; Chen L; Li H; Zhang J; Zhang Y; Zhao H; Yang Y
    Cell Physiol Biochem; 2018; 47(1):293-301. PubMed ID: 29768257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
    Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
    Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma.
    Xu Y; Yuan X; Zhang X; Hu W; Wang Z; Yao L; Zong L
    Medicine (Baltimore); 2021 Jun; 100(25):e26506. PubMed ID: 34160470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
    Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
    Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization.
    Yang Z; Zhang J; Lu Y; Xu Q; Tang B; Wang Q; Zhang W; Chen S; Lu L; Chen X
    Oncotarget; 2015 Dec; 6(40):43090-8. PubMed ID: 26506519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
    Chen ZX; Jian ZW; Wu XW; Wang JC; Peng JY; Lao XM
    Cancer Med; 2019 Sep; 8(11):5097-5107. PubMed ID: 31313476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating Up-to-Seven Criteria and APRI (AST Platelet Ratio) as Prognostic Factors in Intermediate-Stage Hepatocellular Carcinoma Patients Who Received Transarterial Chemoembolization.
    Inmutto N; Nimitrungtawee N; Srisuwan T; Kattipathanapong T; Jantarangkoon A; Puttisri O
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3939-3946. PubMed ID: 36444608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.